Estrella Immunopharma Inc (ESLA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.41-7.53%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · ESLA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers · Company calendar date is not available
ESLA — CEO transition
Dated 2026-10-29
CEO — Cynthia Pussinen: An external hire was appointed as CEO and Board Chair, replacing the previous CEO who transitioned to an internal role, representing a significant leadership change but not a loss of executive talent.
Why it matters: ESLA already received a Nasdaq notice over its bid price. A new notice would point to continued listing pressure.
Worry ifNasdaq sends a new notice that ESLA’s bid price fell below $1 for 30 straight business days.
Less concerning ifESLA reports that Nasdaq closed the bid-price matter after the share-price test was met.
Why it matters: Nasdaq flagged a share price below $1 for 30 straight business days. A compliance update will show whether this listing risk remains.
Worry ifNasdaq confirms ESLA’s closing bid price stayed at or above $1 for 10 straight business days.
Less concerning ifNasdaq says ESLA missed its bid-price deadline or moves to delist the shares.
Why it matters: Nasdaq flagged market value below $35 million for 30 straight business days. Regaining compliance may reduce listing risk.
Worry ifNasdaq says ESLA met the $35 million market-value rule by the December 2026 deadline.
Less concerning ifNasdaq says ESLA failed to meet the rule by the deadline or starts delisting proceedings.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$318 on $10,000 · ±3.2% | How much price usually moves either way. |
| Bad day | $1,232 loss on $10,000 · 12.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,928 loss on $10,000 · 89.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.